- Home
- SDSTW vs AIDX Comparison
SDSTW vs AIDX Comparison
Compare SDSTW & AIDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SDSTW | AIDX |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 10 | 14 |
| Industry | | Precision Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8M | 6.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SDSTW | AIDX |
|---|---|---|
| Price | $0.15 | $0.43 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.9K | ★ 124.8K |
| Earning Date | 03-26-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.04 | $0.40 |
| 52 Week High | $0.30 | $14.09 |
Technical Indicators
Market Signals| Indicator | SDSTW | AIDX |
|---|---|---|
| Relative Strength Index (RSI) | 39.08 | 29.57 |
| Support Level | N/A | N/A |
| Resistance Level | $0.12 | $0.57 |
| Average True Range (ATR) | 0.01 | 0.04 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 1.73 | 15.90 |
Price Performance
Historical ComparisonAbout SDSTW Stardust Power Inc. Warrant
Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).
About AIDX 20/20 Biolabs Inc. Common Stock
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.